Using a mouse model in which tumors show a growth-regression-recurrence pattern, we investigated the mechanisms for down-regulation of cytotoxic T lymphocyte–mediated tumor immuno-surveillance.

Drug candidate eliminates breast cancer tumors in mice in a single dose. ScienceDaily . Retrieved February 1, 2025 from www.sciencedaily.com / releases / 2025 / 01 / 250122130055.htm ...

To assess the therapy's performance in vivo, the team used a mouse model of subcutaneous gastric cancer. Mice treated with As@LNPs experienced slower tumor growth, smaller tumor sizes, and ...

Despite significant therapeutic advances, breast cancer remains a leading cause of cancer-related death in women. Treatment typically involves surgery and follow-up hormone therapy, but late ...

Pharmatest Services has announced it has collaborated with Taconic Biosciences to develop a novel humanised mouse model of tumour ...

In a key study using immune-competent balb/c mice, BNCT treatment of subcutaneous tumors on one leg completely inhibited tumor growth when the same tumor cells were reintroduced to the opposite ...

The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo ...

Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed ...